Dennis Porto, MD and Riyaz Farhaad, MD have launched AcneAlly.com, an online service that allows patients access to a board certified dermatologist and a standardized approach to assessment and long-term monitoring. Julie Harper, MD discusses findings from “Beyond the visible: Rosacea and psoriasis of the face;” the report supported by Galderma provides findings of a global survey involving over 600 patients with facial rosacea or psoriasis and 361 doctors across six countries. Dr. Shereene Idriss discusses Galderma’s “Face Up to Rosacea” campaign featuring celebrity stylist and E! TV personality Brad Goreski. The 300mg single-dose pre-filled pen for Dupixent is now available. MC2 Therapeutics is partnering with EPI Health on the commercialization of Wynzora Cream in the US.
A feasibility study in collaboration between LEO Innovation Lab, VisualDX, and the German Association of Dermatological Prevention supports technology to assist in diagnosis of skin conditions. Leo Pharma’s investigational JAK inhibitor delgocitinib cream is Fast Tracked by the FDA for the potential treatment of adults with moderate-to-severe chronic hand eczema. Two new studies reinforce the efficacy and safety of Dupixent for the treatment of atopic dermatitis in children and adults. Stelara is now approved for pediatric patients, 6-11 years of age, with moderate to severe plaque psoriasis. Look for Rihanna’s new Fenty Skin line under the umbrella of skincare offerings.
The vast majority of dermatologists around the world—95.6 percent—believe climate change is occurring, and 88 percent think it will impact the incidence of skin diseases, according to the first international survey of dermatologists on the topic, conducted online by the International Society of Dermatology's Climate Change Committee. FDA has approved MC2 Therapeutics Wynzora Cream for once-daily topical treatment of plaque psoriasis in adults. Tremfya is the first IL-23 inhibitor FDA-approved for active psoriatic arthritis. AbbVie's upadacitinib met both primary and all secondary endpoints in Measure Up 2, the second Phase 3 study in individuals with moderate to severe atopic dermatitis.
It's a "super-exciting" time in the world of atopic dermatitis because of a number of new developments happening very rapidly, shares Peter Lio, MD. Recent approvals and additional indications for treatments like dupilumab and crisaborole in pediatric populations have been welcome additions. And there are biologics—IL-13 and IL-31 inhibitors—and JAK inhibitors in the pipeline showing promise.
From new treatment guidelines to emerging biologic therapies for psoriasis in pediatric patients, Lawrence Eichenfield, MD says there’s new hope in successfully treating this patient population. He also discusses advances in treating pediatric atopic dermatitis.
DermWireTV: LEO Science & Tech Hub, Allergan/SkinBetter DREAM Initiative, San Diego Dermatology Symposium
Amytrx Therapeutics Comes Out of the Gate Strong with Lead Program AMTX-100, Clinical Development Plans
Lilly Launches Digital Health Open Innovation Challenge to Help Transform AD Care
Call for Entries: Sanofi Genzyme and Regeneron Launches 2020 ‘Agents of Change’ AD Challenge
Medicine X Launches Eczema Xplained Patient Story To Drive Understanding and Awareness of AD
DermWireTV: AcneAlly Launches, Rosacea Insights, MC2/EPI Collaboration
DermWireTV: Clinical Support Tech Data; Dupixent, Stelara Updates; Rihanna Launches Fenty Skin
New Data Supports the Safety and Efficacy of Dupixent in Adults and Children with AD
New Dermatology Atlas to Highlight and Compare Features of Common Dermatologic Conditions in Different Skin Types